Raguin G, Lê Thi Huong D, Piette J C, Bletry O, Renou P, Guillevin L, Langlois P, Godeau P
Service de Médecine interne, Groupe hospitalier Pitié-Salpêtrière, Paris.
Presse Med. 1989 Oct 28;18(35):1739-42.
Between 1976 and 1988, 7 patients with systemic lupus erythematosus (SLE) underwent splenectomy for severe peripheral thrombocytopenia (platelet count below 30,000/mm3) which had resisted corticosteroid therapy (n = 7), high-dose immunoglobulins (n = 4), vincristine (n = 2), danazol (n = 1), cyclophosphamide and plasma exchanges (n = 1). No infective or non-infective complication of splenectomy was observed. One patient died of intracerebral haemorrhage 3 years later, after several recurrences of thrombocytopenia. The 6 survivors have normal platelet counts (more than 150,000/mm3) after splenectomy, over a mean follow-up period of 80 months. Two of these 6 patients never had recurrent thrombocytopenia and have not received any treatment for 17 to 102 months. Four patients are still under prednisone in doses lower than 30 mg/day. Among these, 2 had recurrent thrombocytopenia 2 and 60 months respectively after splenectomy and responded favourably to another course of corticosteroids associated, in one case, with cyclophosphamide. Thus, splenectomy is an effective treatment of the thrombocytopenia associated with SLE. However, the possibility of early or late recurrences makes it necessary to reserve splenectomy to those cases where medical treatment has failed or is contra-indicated.
1976年至1988年间,7例系统性红斑狼疮(SLE)患者因严重外周血小板减少(血小板计数低于30,000/mm³)接受了脾切除术,这些患者对皮质类固醇治疗(n = 7)、大剂量免疫球蛋白(n = 4)、长春新碱(n = 2)、达那唑(n = 1)、环磷酰胺和血浆置换(n = 1)均无效。未观察到脾切除术后的感染性或非感染性并发症。1例患者在血小板减少多次复发后3年死于脑出血。6名幸存者在脾切除术后血小板计数正常(超过150,000/mm³),平均随访期为80个月。这6例患者中有2例从未复发血小板减少,且在17至102个月内未接受任何治疗。4例患者仍在服用剂量低于30 mg/天的泼尼松。其中,2例分别在脾切除术后2个月和60个月复发血小板减少,对另一疗程的皮质类固醇治疗反应良好,其中1例联合环磷酰胺。因此,脾切除术是治疗SLE相关血小板减少的有效方法。然而,早期或晚期复发的可能性使得有必要将脾切除术保留给那些药物治疗失败或禁忌的病例。